AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Dr. Rachael A. Safyan on Pancreatic Cancer: Evolving Treatment Paradigms from Resectable to Metastatic Disease
By The Cancer News Team
Dr. Rachael A. Safyan reviews evolving treatment strategies in pancreatic cancer, from neoadjuvant therapy and tumor-treating fields to RAS-targeted agents reshaping metastatic care.
Dr. Rachael A. Safyan on Pancreatic Cancer: Evolving Treatment Paradigms from Resectable to Metastatic Disease
By The Cancer News Team
Dr. Rachael A. Safyan reviews evolving treatment strategies in pancreatic cancer, from neoadjuvant therapy and tumor-treating fields to RAS-targeted agents reshaping metastatic care.
Dr. Rachael A. Safyan on Pancreatic Cancer: Evolving Treatment Paradigms from Resectable to Metastatic Disease
By The Cancer News Team
Dr. Rachael A. Safyan reviews evolving treatment strategies in pancreatic cancer, from neoadjuvant therapy and tumor-treating fields to RAS-targeted agents reshaping metastatic care.
Dr. Emerson Y. Chen on Perioperative Chemoimmunotherapy and HER2-Directed Therapies in Resectable and Advanced Gastric Cancer
By The Cancer News Team
Dr. Emerson Y. Chen reviews MATTERHORN, HERIZON-GEA-01, and DESTINY-Gastric04, highlighting perioperative nivolumab plus FLOT and next-generation HER2-directed therapies in advanced gastroesophageal cancer.
Dr. Emerson Y. Chen on Perioperative Chemoimmunotherapy and HER2-Directed Therapies in Resectable and Advanced Gastric Cancer
By The Cancer News Team
Dr. Emerson Y. Chen reviews MATTERHORN, HERIZON-GEA-01, and DESTINY-Gastric04, highlighting perioperative nivolumab plus FLOT and next-generation HER2-directed therapies in advanced gastroesophageal cancer.
Dr. Emerson Y. Chen on Perioperative Chemoimmunotherapy and HER2-Directed Therapies in Resectable and Advanced Gastric Cancer
By The Cancer News Team
Dr. Emerson Y. Chen reviews MATTERHORN, HERIZON-GEA-01, and DESTINY-Gastric04, highlighting perioperative nivolumab plus FLOT and next-generation HER2-directed therapies in advanced gastroesophageal cancer.
Why Indigenous Communities Face Higher Cancer Rates
By Jin Mou, MD, MSc, MPH, PhD
New data show Indigenous communities face higher rates of gallbladder and biliary cancers, with emerging research suggesting distinct genetic and biological drivers in Alaska Native and Pacific Islander populations.
Why Indigenous Communities Face Higher Cancer Rates
By Jin Mou, MD, MSc, MPH, PhD
New data show Indigenous communities face higher rates of gallbladder and biliary cancers, with emerging research suggesting distinct genetic and biological drivers in Alaska Native and Pacific Islander populations.
Why Indigenous Communities Face Higher Cancer Rates
By Jin Mou, MD, MSc, MPH, PhD
New data show Indigenous communities face higher rates of gallbladder and biliary cancers, with emerging research suggesting distinct genetic and biological drivers in Alaska Native and Pacific Islander populations.
Can a Blood Test Detect Cancer Earlier? What to Know About Liquid Biopsy
By The Cancer News Team
A new study suggests multicancer blood tests could shift cancer diagnoses to earlier stages. Here’s what liquid biopsy is, how MCED tests work, current FDA approvals, benefits, risks, and what patients should know.
Can a Blood Test Detect Cancer Earlier? What to Know About Liquid Biopsy
By The Cancer News Team
A new study suggests multicancer blood tests could shift cancer diagnoses to earlier stages. Here’s what liquid biopsy is, how MCED tests work, current FDA approvals, benefits, risks, and what patients should know.
Can a Blood Test Detect Cancer Earlier? What to Know About Liquid Biopsy
By The Cancer News Team
A new study suggests multicancer blood tests could shift cancer diagnoses to earlier stages. Here’s what liquid biopsy is, how MCED tests work, current FDA approvals, benefits, risks, and what patients should know.
Dr. Julia Zhang on Challenging Treatment Dogma: Early Bispecific Antibody Use in Relapsed Myeloma
By The Cancer News Team
An expert panel at Best of Hematology & Breast Cancer 2026 debates early use of bispecific antibodies versus CAR T-cell therapy in an 83-year-old patient with relapsed multiple myeloma.
Dr. Julia Zhang on Challenging Treatment Dogma: Early Bispecific Antibody Use in Relapsed Myeloma
By The Cancer News Team
An expert panel at Best of Hematology & Breast Cancer 2026 debates early use of bispecific antibodies versus CAR T-cell therapy in an 83-year-old patient with relapsed multiple myeloma.
Dr. Julia Zhang on Challenging Treatment Dogma: Early Bispecific Antibody Use in Relapsed Myeloma
By The Cancer News Team
An expert panel at Best of Hematology & Breast Cancer 2026 debates early use of bispecific antibodies versus CAR T-cell therapy in an 83-year-old patient with relapsed multiple myeloma.
Dr. Andrew J. Cowan on Frontline Therapy of Multiple Myeloma: Advances from ASH 2025
By The Cancer News Team
Dr. Andrew J. Cowan reviews ASH 2025 updates in frontline multiple myeloma, including MRD dynamics, t(11;14), Duffy null genotype, functional high-risk disease, CD38 maintenance, and emerging bispecific strategies.
Dr. Andrew J. Cowan on Frontline Therapy of Multiple Myeloma: Advances from ASH 2025
By The Cancer News Team
Dr. Andrew J. Cowan reviews ASH 2025 updates in frontline multiple myeloma, including MRD dynamics, t(11;14), Duffy null genotype, functional high-risk disease, CD38 maintenance, and emerging bispecific strategies.
Dr. Andrew J. Cowan on Frontline Therapy of Multiple Myeloma: Advances from ASH 2025
By The Cancer News Team
Dr. Andrew J. Cowan reviews ASH 2025 updates in frontline multiple myeloma, including MRD dynamics, t(11;14), Duffy null genotype, functional high-risk disease, CD38 maintenance, and emerging bispecific strategies.
Dr. Thomas DeLoughery on Evolving Treatment Strategies in Immune Thrombocytopenia
By The Cancer News Team
Dr. Thomas DeLoughery reviews evolving treatment strategies for immune thrombocytopenia and autoimmune hemolytic anemia, highlighting thrombopoietin agonists, BTK inhibitors, anti-CD38 antibodies, and complement-targeted therapies.
Dr. Thomas DeLoughery on Evolving Treatment Strategies in Immune Thrombocytopenia
By The Cancer News Team
Dr. Thomas DeLoughery reviews evolving treatment strategies for immune thrombocytopenia and autoimmune hemolytic anemia, highlighting thrombopoietin agonists, BTK inhibitors, anti-CD38 antibodies, and complement-targeted therapies.
Dr. Thomas DeLoughery on Evolving Treatment Strategies in Immune Thrombocytopenia
By The Cancer News Team
Dr. Thomas DeLoughery reviews evolving treatment strategies for immune thrombocytopenia and autoimmune hemolytic anemia, highlighting thrombopoietin agonists, BTK inhibitors, anti-CD38 antibodies, and complement-targeted therapies.
Dr. Hannah Linden on Management of ER-Positive Metastatic Breast Cancer After CDK4/6 Inhibitor Therapy
By The Cancer News Team
Dr. Hannah Linden reviews treatment strategies for ER-positive metastatic breast cancer after CDK4/6 inhibitors, highlighting SERDs, combination therapies, ESR1 mutation testing, and emerging imaging tools.
Dr. Hannah Linden on Management of ER-Positive Metastatic Breast Cancer After CDK4/6 Inhibitor Therapy
By The Cancer News Team
Dr. Hannah Linden reviews treatment strategies for ER-positive metastatic breast cancer after CDK4/6 inhibitors, highlighting SERDs, combination therapies, ESR1 mutation testing, and emerging imaging tools.
Dr. Hannah Linden on Management of ER-Positive Metastatic Breast Cancer After CDK4/6 Inhibitor Therapy
By The Cancer News Team
Dr. Hannah Linden reviews treatment strategies for ER-positive metastatic breast cancer after CDK4/6 inhibitors, highlighting SERDs, combination therapies, ESR1 mutation testing, and emerging imaging tools.
Dr. Vidhya Nair on De-escalation and Personalized Treatment in HER2-Positive Breast Cancer
By The Cancer News Team
Dr. Vidhya Nair reviews key advances in HER2-positive breast cancer, highlighting de-escalation in early-stage disease, T-DXd in high-risk and metastatic settings, and evolving personalized treatment strategies.
Dr. Vidhya Nair on De-escalation and Personalized Treatment in HER2-Positive Breast Cancer
By The Cancer News Team
Dr. Vidhya Nair reviews key advances in HER2-positive breast cancer, highlighting de-escalation in early-stage disease, T-DXd in high-risk and metastatic settings, and evolving personalized treatment strategies.
Dr. Vidhya Nair on De-escalation and Personalized Treatment in HER2-Positive Breast Cancer
By The Cancer News Team
Dr. Vidhya Nair reviews key advances in HER2-positive breast cancer, highlighting de-escalation in early-stage disease, T-DXd in high-risk and metastatic settings, and evolving personalized treatment strategies.
Dr. Xiaowen Wang on Optimizing Patient Selection in Advanced ER-Positive Breast Cancer
By The Cancer News Team
Dr. Xiaowen Wang reviews evolving strategies for advanced ER-positive metastatic breast cancer, highlighting NGS timing, ESR1 and PIK3CA mutations, novel SERDs, and targeted combination therapies.
Dr. Xiaowen Wang on Optimizing Patient Selection in Advanced ER-Positive Breast Cancer
By The Cancer News Team
Dr. Xiaowen Wang reviews evolving strategies for advanced ER-positive metastatic breast cancer, highlighting NGS timing, ESR1 and PIK3CA mutations, novel SERDs, and targeted combination therapies.
Dr. Xiaowen Wang on Optimizing Patient Selection in Advanced ER-Positive Breast Cancer
By The Cancer News Team
Dr. Xiaowen Wang reviews evolving strategies for advanced ER-positive metastatic breast cancer, highlighting NGS timing, ESR1 and PIK3CA mutations, novel SERDs, and targeted combination therapies.